FDA De Novo Classification: Pathway Requirements, Process, and How to Create a New Device Category

What Is the De Novo Classification Pathway?

The De Novo classification pathway is the FDA's mechanism for authorizing novel medical devices that are low-to-moderate risk but have no legally marketed predicate device. It exists under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic (FD&C) Act and is administered by the Center for Devices and Radiological Health (CDRH) and, for certain biologics-related devices, the Center for Biologics Evaluation and Research (CBER).

Unlike a 510(k) — which requires you to identify a predicate and demonstrate substantial equivalence — a De Novo request asks the FDA to evaluate your device on its own merits and classify it into Class I (general controls) or Class II (general controls plus special controls). The standard of review is "reasonable assurance of safety and effectiveness," the same standard applied to PMA applications, but applied in the context of lower-risk devices where general controls or general and special controls are sufficient.

A successful De Novo does not just authorize a single device for marketing. It creates an entirely new classification regulation under 21 CFR, assigns a new three-letter product code, and establishes the special controls (if Class II) that will govern all future devices of that type. The De Novo device then becomes the first predicate that subsequent manufacturers can reference in 510(k) submissions. This is what makes De Novo fundamentally different from both 510(k) and PMA — it is a classification pathway, not merely a marketing authorization pathway.

Key distinction: The FDA "clears" 510(k) devices, "approves" PMA devices, and "grants" De Novo requests. Using the correct terminology signals regulatory fluency.

History and Evolution of the De Novo Pathway

FDAMA 1997 — The Original "Post-NSE" De Novo

The De Novo pathway was created by the Food and Drug Administration Modernization Act of 1997 (FDAMA). Before FDAMA, any novel device without a predicate that received a Not Substantially Equivalent (NSE) determination through the 510(k) process was automatically classified as Class III — requiring a full PMA submission. This made no sense for low-risk novel devices like new types of bandages or simple diagnostic tools. Congress recognized this gap and added Section 513(f)(2) to the FD&C Act, allowing manufacturers who received an NSE determination to request, within 30 days, that the FDA evaluate the device for Class I or Class II classification based on risk.

This original pathway was cumbersome. You had to first submit a 510(k), receive a formal NSE letter, and only then submit a De Novo petition. The process was slow, and relatively few manufacturers used it — fewer than 5 De Novo requests per year were filed through most of the 2000s.

FDASIA 2012 — The "Direct" De Novo

The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) transformed the De Novo pathway by adding a second, direct submission option. Section 607 of FDASIA amended Section 513(f)(2) to allow manufacturers to submit a De Novo request directly — without first filing a 510(k) and receiving an NSE determination.

This was the single most important change in the pathway's history. It eliminated the redundant 510(k) step and made De Novo a genuinely standalone option for novel devices. Use of the pathway increased significantly after 2012, and the direct De Novo is now the dominant route — the original post-NSE pathway is rarely used.

2016 — 21st Century Cures Act

The 21st Century Cures Act, enacted in December 2016, further modified the De Novo process. The Cures Act removed the previous 30-day submission window requirement for post-NSE De Novo requests and made additional modifications to streamline the classification process. It also reinforced FDA's commitment to innovation-friendly pathways and contributed to the expanding scope of De Novo eligibility, including explicit applicability to certain combination products (device-led combination products where the device constituent part is novel and low-to-moderate risk).

2017 Final Guidance and 21 CFR Part 860, Subpart D

In 2017, the FDA published its final guidance document, "De Novo Classification Process (Evaluation of Automatic Class III Designation)," which established detailed procedures for submission, review, and decision-making. This was followed by the October 2021 final rule codifying the De Novo process in 21 CFR Part 860, Subpart D, which provided regulatory certainty and formalized requirements that had previously existed only in guidance. Notably, the final rule explicitly provides a pathway for certain combination products to obtain marketing authorization through De Novo classification, broadening the pathway's applicability beyond standalone devices.

2024–2025 — eSTAR and Modernization

In August 2024, the FDA finalized guidance on the Electronic Submission Template (eSTAR) for De Novo requests (FDA-2023-D-3788). Beginning October 1, 2025, all De Novo submissions must use the eSTAR template and be submitted electronically through the CDRH Customer Collaboration Portal, unless an exemption applies. This aligns De Novo with the eSTAR requirements already in place for 510(k) submissions and marks a significant modernization of the submission process.

Also in 2024, the FDA finalized the Predetermined Change Control Plan (PCCP) guidance, which has particular significance for De Novo devices. The PCCP framework allows AI/ML-enabled devices to include a pre-authorized plan for algorithm modifications in their initial marketing submission — including De Novo requests. This addresses a long-standing challenge for AI/ML devices going through De Novo: the need to update algorithms post-market without filing a new marketing submission for each change.

Timeline of Key De Novo Regulatory Milestones

Year	Milestone
1976	Medical Device Amendments establish device classification system; no De Novo pathway exists
1997	FDAMA creates Section 513(f)(2) — "post-NSE" De Novo for devices found Not Substantially Equivalent
2012	FDASIA Section 607 creates "direct" De Novo option — no prior 510(k) required
2014	FDA establishes dedicated De Novo review staff and processes within CDRH
2016	21st Century Cures Act removes 30-day submission window requirement; confirms De Novo applicability for certain combination products
2017	FDA publishes final guidance on De Novo Classification Process
2018	Landmark De Novo authorizations (Apple Watch ECG, IDx-DR) demonstrate pathway viability for breakthrough technologies
2021	Final rule codifies De Novo in 21 CFR Part 860, Subpart D; formal regulatory certainty achieved
2022	MDUFA V establishes De Novo-specific performance goals (150 FDA days, 70% target) for FY2023-2027
2024	eSTAR guidance finalized for De Novo; PCCP guidance finalized for AI/ML devices
2025	eSTAR mandatory for all De Novo submissions (October 1); record submission volumes continue

When to Use De Novo vs. 510(k) vs. PMA

Choosing the wrong FDA pathway wastes months of work and significant money. The decision comes down to three questions: Does a predicate exist? What is the risk level? What standard of review applies?

The Decision Tree

Start here: Can you identify a legally marketed predicate device?

1. Yes, a predicate exists and your device has the same intended use and similar technological characteristics (or different characteristics that do not raise new questions of safety and effectiveness) → 510(k) is your pathway.

2. No predicate exists, but your device is low-to-moderate risk and general controls alone (Class I) or general and special controls (Class II) can provide reasonable assurance of safety and effectiveness → De Novo is your pathway.

3. No predicate exists and the device is high-risk, or general and special controls are insufficient to provide reasonable assurance of safety and effectiveness → PMA is your pathway.

4. A predicate exists, but FDA has determined through reclassification or a PMA call that the device type now requires a PMA → PMA regardless of the predicate.

Common mistake: Trying to force-fit a 510(k) when no true predicate exists. Reviewers will reject it at Refuse to Accept (RTA) or issue an NSE determination. If your device is genuinely novel but low-to-moderate risk, De Novo is the correct path — and a successful De Novo creates a new product code that future competitors can reference as a predicate.

How Novel Does Your Device Need to Be?

"Novel" does not necessarily mean the technology is brand new. It means no existing product code adequately describes your device's intended use and technological characteristics. You might have a device that uses well-established technology in a new way, targets a new patient population, or addresses a new clinical indication — any of these can make De Novo appropriate even if the underlying technology is not revolutionary.

The FDA also appears to be more rigorously interpreting the meaning of "intended use" in recent years. Devices that might previously have been eligible for a 510(k) under a broad interpretation of a predicate's intended use may now require a De Novo submission because the FDA views the intended use as sufficiently different.

Real-World Pathway Decision Scenarios

Scenario 1: AI-powered skin lesion analysis app. You have developed a mobile application that uses AI to analyze photos of skin lesions and provide a risk assessment. No existing product code covers autonomous AI-based dermatological screening software for consumer use. There are 510(k)-cleared dermatoscopes and CAD software for dermatology, but your device's intended use (autonomous consumer screening without physician oversight) is fundamentally different. The device is low-to-moderate risk — it is a screening tool, not a diagnostic. → De Novo is the correct pathway.

Scenario 2: Modified pulse oximeter with new sensor design. You have a pulse oximeter that uses a novel optical sensor configuration but measures the same parameters (SpO2 and pulse rate) as existing cleared devices. Product code DQA exists. Several predicate devices are available. → 510(k) is the correct pathway. The technological difference (sensor configuration) does not raise new questions of safety and effectiveness for the same intended use.

Scenario 3: Implantable neurostimulator for a new neurological indication. You have a novel implantable neurostimulation device intended to treat a condition for which no device has been approved. The device is implanted and carries significant risk. General and special controls would be insufficient to provide reasonable assurance of safety and effectiveness. → PMA is the correct pathway.

Scenario 4: Software that analyzes existing ECG data for a new cardiac condition. ECG software exists, but your software detects a cardiac condition that no cleared software currently targets. The underlying technology (ECG analysis) is well-established, but the specific intended use is new. The device is moderate risk — it provides clinical decision support, not autonomous diagnosis. → De Novo is likely the correct pathway, though you should confirm with a Pre-Sub. The novel intended use means no existing product code covers your device, even though the technology platform is familiar.

When De Novo Is NOT the Right Choice

Pursuing De Novo when another pathway is appropriate wastes time and money. Avoid the De Novo pathway if:

• A suitable predicate device exists — even if your device uses different technology, if an existing product code covers your intended use and your technological differences do not raise new questions of safety and effectiveness, a 510(k) is more appropriate. Do not use De Novo to avoid the burden of identifying and defending a predicate.
• Your device is high-risk — if general controls or general and special controls cannot provide reasonable assurance of safety and effectiveness (e.g., life-sustaining implantable devices, devices treating life-threatening conditions with significant risk of harm), PMA is required regardless of whether a predicate exists.
• You are trying to circumvent 510(k) requirements — De Novo is not an alternative to 510(k) for devices that have predicates. If the FDA identifies a predicate during review, your De Novo will be declined and you will have wasted the higher user fee and additional preparation time.
• Your device type has already been classified through a prior De Novo — if another manufacturer has already obtained a De Novo grant for the same device type and their device can serve as a predicate for yours, a 510(k) referencing that predicate is the correct pathway. Always check the FDA's De Novo Decision Summaries database before assuming no classification exists.
• You lack the resources for the full process — De Novo requires substantially more investment than a 510(k) in terms of user fees, preparation time, clinical data, and special controls development. If your organization cannot commit to a 12–18 month timeline and $300K+ budget, consider whether a 510(k) with a creatively identified predicate might be feasible first. Confirm with a Pre-Sub before committing to either pathway.

Total Cost of a De Novo Submission

Understanding the full cost profile of a De Novo is essential for planning. The user fee is only a fraction of the total investment.

Cost Breakdown

Cost Component	Estimated Range	Notes
MDUFA user fee	$43,446–$173,782	Small business vs. standard rate (FY2026)
Pre-Submission preparation	$15,000–$50,000	Regulatory consultant fees, preparation, meeting attendance
Non-clinical testing	$50,000–$500,000+	Bench testing, biocompatibility, electrical safety, software V&V, EMC, cybersecurity — varies enormously by device type
Clinical study	$100,000–$2,000,000+	If required (~80% of De Novos). Includes study design, site costs, monitoring, data management, statistical analysis. Simple single-site studies at the low end; multi-site pivotal studies at the high end
Regulatory submission preparation	$50,000–$200,000	Drafting submission, special controls, benefit-risk analysis, labeling, eSTAR formatting
Quality system establishment	$50,000–$200,000	If you do not already have a compliant QMS — design controls, document control, CAPA, etc.
AI response preparation	$10,000–$100,000 per round	Addressing FDA's Additional Information requests — may require additional testing
Total estimated range	$300,000–$3,000,000+	Varies significantly by device type, clinical data needs, and organizational maturity

Context: Compare this to a typical 510(k) total cost of $50,000–$500,000 or a PMA total cost of $500,000–$10,000,000+. De Novo sits in the middle — more expensive than 510(k) but typically far less costly than PMA.

These estimates assume you are working with experienced regulatory consultants. Companies with in-house regulatory expertise at the senior level can reduce consultant costs, but the testing, clinical study, and user fee costs remain regardless.

De Novo Application Process: Step by Step

Step 1: Conduct a Thorough Predicate Search

Before pursuing De Novo, you must demonstrate that no suitable predicate exists. This is not optional — it is a core element of the De Novo submission. Your predicate search should cover:

• FDA Product Classification Database (accessdata.fda.gov) — search by device name, product code, and regulation number
• 510(k) Premarket Notification Database — search for cleared devices with similar intended use or technology
• De Novo Decision Summaries Database — check whether a De Novo has already been granted for a similar device type
• PMA Database — search for approved Class III devices that may overlap
• FDA Adverse Event / MAUDE Database — may reveal marketed devices not captured in other searches
• Published literature and patent databases — can identify devices that exist but may not appear in FDA databases

Document your search methodology in detail: databases queried, search terms used, date ranges, number of results reviewed, and your rationale for concluding that no predicate exists. The FDA will scrutinize this analysis, and reviewers may conduct their own independent search.

If a reviewer identifies a potential predicate you missed, your De Novo request may be declined and you will be redirected to the 510(k) pathway. This is one of the most avoidable reasons for a De Novo decline — and it wastes months of preparation time and the substantial user fee.

Step 2: Submit a Pre-Submission (Q-Sub)

A Pre-Submission (Pre-Sub) meeting with the FDA is not technically required, but it is critically important for De Novo requests. The FDA strongly encourages it, and experienced regulatory professionals consider it essentially mandatory.

In the Pre-Sub, you can obtain FDA feedback on:

• Whether De Novo is the appropriate pathway (vs. 510(k) or PMA)
• The proposed classification (Class I vs. Class II)
• Proposed special controls
• Non-clinical testing requirements
• Whether clinical data is needed, and if so, the study design
• Proposed intended use and indications for use
• Proposed labeling

The Pre-Sub process typically takes 60–90 days from submission to the feedback meeting. For a De Novo — where you are establishing an entirely new regulatory framework — this feedback is invaluable. It can prevent you from spending months developing a submission that FDA considers incomplete or misdirected.

Practical tip: Submit your Pre-Sub as early as possible. Do not wait until your testing is complete. The Pre-Sub is where you validate your entire regulatory strategy — your proposed intended use, your classification argument, your testing plan, and your special controls. Getting FDA alignment on these before you finalize your data package can save 6–12 months and hundreds of thousands of dollars.

Step 3: Develop Special Controls (for Class II)

If you are proposing Class II classification — which is the case for the vast majority of De Novo requests — you must develop a comprehensive set of proposed special controls. These are the specific mitigation measures that, together with general controls, provide reasonable assurance of safety and effectiveness for your device type.

Special controls can include:

• Performance testing standards — specific bench tests, electrical safety tests, biocompatibility tests, or software validation requirements
• Labeling requirements — specific warnings, contraindications, or use instructions
• Design controls — requirements tied to 21 CFR 820 (or the new QMSR under 21 CFR 820 as harmonized with ISO 13485)
• Post-market surveillance — requirements for tracking, adverse event reporting, or registry participation
• Clinical performance requirements — minimum sensitivity, specificity, or clinical endpoints
• Patient or user training — requirements for specific training before use

Your proposed special controls must be tied directly to an identified risk. The FDA expects a risk-based justification: for each risk, identify the special control that mitigates it. This is where your risk analysis (per ISO 14971) intersects directly with your regulatory strategy.

Step 4: Generate Non-Clinical and Clinical Evidence

Non-clinical testing is required for virtually all De Novo requests. The scope depends on your device but may include:

• Bench performance testing (functionality, accuracy, precision, reliability)
• Biocompatibility testing (per ISO 10993 series)
• Electrical safety and electromagnetic compatibility (IEC 60601 series)
• Software verification and validation (per IEC 62304, FDA software guidance)
• Cybersecurity documentation (for connected devices)
• Sterilization validation (for sterile devices)
• Shelf life / packaging validation
• Usability / human factors engineering (IEC 62366)

Clinical data is required for the majority of De Novo submissions. Approximately 80% of De Novo requests include clinical studies. However, clinical data is not universally required — the determination depends on the device's risk profile, the nature of the intended use, and whether non-clinical evidence alone can provide reasonable assurance of safety and effectiveness.

When clinical data is needed, it can come from:

• Prospective clinical studies (the most common form) — FDA may expect a pivotal study with pre-specified endpoints, a statistical analysis plan, and enrollment targets. For diagnostic devices, sensitivity and specificity endpoints are typical. For therapeutic devices, safety and effectiveness endpoints must be defined.
• Retrospective clinical data or real-world evidence — the FDA finalized guidance on real-world evidence for device sponsors in 2024, expanding the scenarios under which retrospective data may be acceptable. However, prospective data is generally preferred for De Novo devices because there is no predicate history to draw upon.
• Published literature — If sufficiently relevant and rigorous, literature can supplement or, in rare cases, replace a prospective clinical study. The submission must include a systematic review methodology, inclusion/exclusion criteria, and a critical appraisal of the evidence quality.
• Clinical experience data from outside the US — Foreign clinical data can be accepted if the study was conducted in accordance with good clinical practice (GCP), the study population is relevant to the US patient population, and the data quality meets FDA standards. This is governed by FDA's guidance on acceptance of clinical data to support medical device applications.

Practical tip: Do not assume you can avoid clinical data. Confirm clinical evidence requirements with FDA through a Pre-Sub before you finalize your development plan. Discovering late in the process that a clinical study is needed can add 12–24 months to your timeline.

The scope and design of clinical studies should be discussed with FDA during the Pre-Sub process. For De Novo, the study design conversation is especially important because there are no predicate studies to model. You and FDA are defining the evidentiary standard for a new device category from scratch.

Clinical evidence success rates and considerations: Research has shown that approximately one-fifth of De Novo devices were not evaluated in pivotal clinical studies, and approximately one-third of De Novo devices that were evaluated in pivotal studies failed to meet their primary effectiveness endpoints. Despite this, many of these devices were still granted De Novo authorization based on the totality of evidence, secondary endpoints, or other supportive data. This underscores two points: (1) clinical evidence is important but evaluated in context, and (2) a robust benefit-risk argument and well-designed special controls can compensate for imperfect clinical results in some circumstances. However, this should not be taken as license to submit weak clinical data — the FDA evaluates the totality of evidence, and submissions with strong clinical support have significantly higher grant rates and shorter review times.

Step 5: Prepare and Submit the De Novo Request

Starting October 1, 2025, all De Novo submissions must use the eSTAR template and be submitted electronically via the CDRH Customer Collaboration Portal. The eSTAR template guides you through all required content sections, highlights areas where information is missing or potentially erroneous, and incorporates the acceptance review criteria from 21 CFR 860.230(c)(1)(i) through (v).

Key preparation considerations:

• Start early. A well-prepared De Novo submission typically takes 3–6 months to assemble after testing is complete, assuming you have Pre-Sub feedback in hand. Do not underestimate the effort required to draft special controls, compile testing reports, and write a coherent benefit-risk determination.
• Intended use drafting is critical. The intended use statement you submit will become the basis of the new classification regulation. Every word matters. Work with your regulatory team and legal counsel to draft it precisely — too broad and FDA may narrow it; too narrow and you may limit your commercial flexibility.
• Cross-reference your Pre-Sub feedback. If you received FDA feedback through a Pre-Sub, explicitly reference it in your submission and explain how your data package addresses the FDA's recommendations. Reviewers appreciate seeing this alignment documented.
• Include the eSTAR technical screening. FDA employs a virus scanning and technical screening process as part of the acceptance review. Ensure your files are in the correct format, properly named, and free of technical issues that could delay acceptance.

Step 6: Pay the User Fee

The appropriate MDUFA user fee must be paid before FDA will begin its review. For FY2026 (October 1, 2025 – September 30, 2026):

Fee Type	Standard	Small Business
De Novo request	$173,782	$43,446
510(k) (for comparison)	$26,067	$6,517
PMA (for comparison)	$579,272	$144,818

Small business qualification requires enrollment in the FDA's Small Business Determination (SBD) program with gross receipts or sales of $100 million or less.

Note on cost: The De Novo user fee is roughly 6.7x the 510(k) fee but only 30% of the PMA fee. When you factor in the typically shorter timeline and lower clinical data requirements compared to PMA, De Novo often represents the most cost-effective path for novel low-to-moderate-risk devices.

User Fee Exceptions, Refunds, and Special Circumstances

Understanding when fees are required, when exceptions apply, and when refunds are available can save significant money, particularly for smaller companies:

Fee exceptions:

• Pediatric-only devices — De Novo requests intended solely for a pediatric population (patients age 21 or younger) are exempt from the De Novo user fee under Section 738(a)(2)(B)(v) of the FD&C Act. This is a meaningful incentive for pediatric device innovation.
• Devices under Humanitarian Device Exemption (HDE) — not applicable to De Novo, but worth noting for pathway comparison.

When the FDA will refund a De Novo user fee:

• You qualify for a fee exception that was not applied at the time of payment
• You fail to submit a valid eCopy before your original De Novo request is accepted for review (refund upon request)
• The FDA determines during review that your submission does not meet the acceptance criteria (refund upon request)

When the FDA will NOT refund a De Novo user fee:

• Your De Novo request is declined after substantive review
• You voluntarily withdraw your De Novo request after it has been accepted for review
• The FDA considers your request withdrawn (e.g., failure to respond to an AI request within 180 days)

Fees after a decline:

• If your De Novo is declined and you resubmit a new De Novo request, you must pay a new De Novo user fee
• If you switch to a 510(k) after a decline (because a predicate was identified), you pay the 510(k) fee
• If you file a reclassification petition, no user fee is required
• If you switch to PMA, you pay the PMA fee

For full details, consult the FDA's guidance document "User Fees and Refunds for De Novo Classification Requests."

Content Requirements of a De Novo Request

The content requirements for a De Novo request are more extensive than for a 510(k) because you are not simply demonstrating equivalence to a predicate — you are building the entire case for a new classification from the ground up. The FDA must have sufficient information to establish a new classification regulation, define special controls, and determine that the device meets the standard of reasonable assurance of safety and effectiveness.

A complete De Novo submission under eSTAR includes the following major sections:

Administrative Information

• CDRH Premarket Review Submission Cover Sheet
• Applicant and correspondent identification (consistent with Form FDA 3514)
• Form FDA 356h (Application/Premarket Review) — the formal application form for the De Novo request
• Prior submission history for the same device (regulatory history, including any prior 510(k), Pre-Sub, or IDE submissions for the same or related devices)
• Registration and listing information
• Table of contents

Device Description

• Comprehensive description of the device, including all components, accessories, and materials
• Principles of operation
• Intended use and indications for use (precisely drafted — this becomes the basis of the new classification regulation)
• Device design specifications and drawings

Alternate Practices and Procedures

• Description of existing alternative treatments, diagnostics, or devices that address the same condition or clinical need
• Comparison of benefits, risks, and limitations of the proposed device relative to these alternatives
• Justification for why the new device provides value to patients or the healthcare system beyond existing options

Classification Recommendation

• Proposed classification (Class I or Class II)
• Proposed product code (if you have a suggestion)
• Proposed regulation number under 21 CFR
• Identification of the appropriate review panel
• Classification summary explaining why the device is eligible for a De Novo order, referencing classification regulations from similar device types where applicable

Predicate Search and Analysis

• Documentation of your search for legally marketed predicate devices
• Search methodology and databases queried
• Explanation of why no existing device is a suitable predicate

Risk Analysis and Special Controls

• Comprehensive risk analysis identifying all known and foreseeable risks
• For Class II: proposed special controls mapped to identified risks
• Justification for why general controls alone (Class I) or general and special controls (Class II) are sufficient

Non-Clinical Testing Data

• Bench performance data
• Biocompatibility, electrical safety, EMC, software, cybersecurity, sterility, shelf life — as applicable
• Identification of voluntary consensus standards used (FDA-recognized and non-recognized)

Clinical Data (if applicable)

• Clinical study reports
• Study design, endpoints, statistical analysis plan, results
• Adverse events
• For literature-based submissions: systematic review methodology and results

Benefit-Risk Determination

• Summary of probable benefits and probable risks
• Benefit-risk analysis supporting the proposed classification
• Patient preference information (if applicable) — the FDA has published guidance ("Patient Preference Information — Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling") encouraging manufacturers to include patient preference data in De Novo requests. Patient preference studies can provide valuable input on how patients weigh the benefits and risks of a novel device, particularly when the device represents a new treatment or diagnostic paradigm. While not required, patient preference information can strengthen your benefit-risk argument and may be considered during FDA's review.

Labeling

• Proposed device labeling, instructions for use, and any patient-facing materials
• For devices with patient contact: patient labeling written at an appropriate reading level
• For software devices: user interface screenshots and workflow descriptions

Additional Sections (as applicable)

• Reprocessing information — for reusable devices, instructions and validation data for cleaning, disinfection, and sterilization between uses
• Sterility information — sterilization method validation, sterility assurance level, and packaging validation for sterile devices
• Shelf life data — accelerated and real-time aging study data supporting the proposed shelf life
• Biocompatibility — ISO 10993 evaluation for devices with direct or indirect patient contact
• Software documentation — software level of concern, software requirements specification, architecture design, verification and validation testing, cybersecurity risk assessment, and Software Bill of Materials (SBOM) for connected devices
• Electromagnetic compatibility (EMC) — IEC 60601-1-2 testing for electronic devices
• Human factors / usability — per IEC 62366-1 and FDA human factors guidance, including use-related risk analysis, formative studies, and summative (validation) testing results

Special Controls Development: What FDA Expects

The special controls you propose in a De Novo request are not just a regulatory formality — they become the binding requirements for your device type going forward. Every future 510(k) submission referencing your De Novo device as a predicate will need to comply with these special controls. This means your proposed special controls shape the regulatory landscape for your entire device category.

The FDA expects your special controls to:

1. Be specific and measurable — "The device must demonstrate a minimum sensitivity of 90% and specificity of 85% for detection of [condition]" is far more useful than "the device must perform adequately."

2. Map directly to identified risks — Each special control should address one or more risks from your risk analysis. The FDA wants to see the logical chain: Risk → Mitigation → Special Control.

3. Be technologically feasible — The FDA will not accept special controls that future manufacturers cannot reasonably implement.

4. Cover the full lifecycle — Special controls should address design, manufacturing, testing, labeling, and (where appropriate) post-market requirements.

5. Reference recognized standards where possible — Citing IEC 60601-1, ISO 10993, IEC 62304, or other recognized standards as part of your special controls makes them concrete and enforceable.

The FDA will negotiate your proposed special controls during the review process. The final special controls published in the De Novo grant order may differ from what you proposed — FDA may add, modify, or remove controls based on its own assessment.

Example: Special Controls for an AI/ML Diagnostic Device

To illustrate how special controls work in practice, consider a hypothetical De Novo for an AI-based diagnostic software device classified as Class II. The special controls might include:

Risk Identified	Special Control
Incorrect diagnosis due to algorithm error	Clinical performance testing demonstrating minimum sensitivity of 90% and specificity of 85% in the intended patient population
Algorithm degradation over time	Software verification and validation per IEC 62304; description of the machine learning model, training data, and performance evaluation methodology
Cybersecurity vulnerabilities in connected software	Cybersecurity documentation consistent with FDA's premarket cybersecurity guidance, including threat modeling and security risk assessment
Misuse due to unclear intended population	Labeling must clearly state the intended patient population, clinical setting, and conditions under which the device should and should not be used
Bias in AI model across demographic groups	Performance testing stratified by clinically relevant subgroups (age, sex, skin tone, etc.) to demonstrate consistent performance
Interoperability failures with clinical systems	Software interoperability testing and documentation per FDA's interoperability guidance

This type of structured risk-to-control mapping is what FDA expects to see in your De Novo submission. Each special control should be traceable back to a specific identified risk.

Review Timeline and Process

Acceptance Review (Days 1–15)

Within 15 calendar days of receiving your De Novo request, FDA conducts an acceptance review. This is a threshold check for completeness and administrative acceptability — not a substantive review of scientific merit. The FDA checks whether:

• The user fee has been paid
• The submission uses the correct format (eSTAR as of October 1, 2025)
• All required sections are present
• The device description and intended use are clear
• The submission does not duplicate an existing open submission

If deficiencies are found, the submission is placed on Refuse to Accept (RTA) hold. You will receive a letter detailing the deficiencies, and the review clock does not start until you address them. If the FDA does not complete the acceptance review within 15 calendar days, the De Novo request is automatically accepted for review.

The FDA evaluates acceptance against the criteria published in Appendix A of the "Acceptance Review for De Novo Classification Requests" guidance document. Before submitting, review this checklist carefully — it covers all required content elements and formatting requirements. Addressing every item on this checklist before submission is one of the most effective ways to avoid an RTA hold.

Substantive Review (Up to 150 FDA Days)

Once accepted, the FDA conducts a substantive review. Under MDUFA V (FY2023–FY2027), the performance goal is to issue a decision within 150 FDA days for 70% of De Novo requests (with escalating targets for later fiscal years — potentially reaching 80–90% if earlier goals are met).

"FDA days" vs. calendar days: The clock stops when the FDA sends you an Additional Information (AI) request and restarts when you respond. A De Novo with multiple AI rounds can stretch well beyond 150 calendar days. The average total calendar time for a De Novo decision — including time the clock is stopped — has historically been 350–420 calendar days, though this varies significantly by device complexity.

During substantive review, the FDA:

• Evaluates whether a predicate truly does not exist
• Assesses the proposed classification and special controls
• Reviews all non-clinical and clinical data
• Evaluates the benefit-risk determination
• May issue Additional Information (AI) requests — often multiple rounds
• May conduct a pre-decision inspection of your manufacturing facility if there are quality concerns or novel manufacturing processes

Additional Information (AI) Requests

AI requests are the primary mechanism by which FDA communicates questions and deficiencies during the substantive review. For De Novo requests, you should expect at least one AI round — many submissions go through two or three. Each AI round typically involves:

1. FDA issues the AI request — a written document listing specific questions, data gaps, or concerns. The review clock stops on the day the AI request is issued.
2. You prepare your response — this can take weeks to months depending on the complexity. You may need to run additional tests, analyze data differently, revise labeling, or modify your proposed special controls.
3. You submit the response — the review clock restarts on the day the FDA receives your complete response.

Note that before issuing a formal AI request, the FDA may first attempt an interactive review — informal communication (email or phone) to resolve minor questions or clarifications without stopping the clock. Interactive reviews are a faster mechanism for addressing straightforward issues. If the questions cannot be resolved interactively, the FDA escalates to a formal AI request, which does stop the review clock.

Critical deadline: You have 180 calendar days to respond to an AI request or other deficiency communication. If you fail to provide a complete response within 180 days, the FDA considers your De Novo request withdrawn, and you must resubmit from the beginning — including paying a new user fee. This deadline is non-negotiable and strictly enforced.

Strategic advice: Respond to AI requests as quickly and completely as possible. Partial responses or responses that do not directly address the FDA's questions will result in additional AI rounds. Each round adds calendar time and increases the risk of a decline. Assign a dedicated team to AI responses and treat them with the same priority as the original submission.

Pre-Decision Inspections

The FDA may conduct a pre-decision inspection of your manufacturing facility before issuing a decision. This is more common for De Novo than for 510(k) because the novelty of the device may raise manufacturing quality questions. Inspections are particularly likely when:

• Clinical data integrity needs verification
• There are complaints or concerns about clinical investigational sites
• The manufacturing process is novel or complex
• The device involves critical processes that could affect safety and effectiveness

Ensure your facility is inspection-ready before submitting your De Novo request. An inspection finding that raises significant quality concerns can delay or prevent a grant.

Decision

The FDA will issue one of three decisions:

1. Grant — The De Novo request is granted. A new classification regulation is established, a product code is assigned, special controls are defined, and you are authorized to market the device. The FDA publishes a De Novo Decision Summary (accessible on the FDA website) and issues a Federal Register notice establishing the new classification.

2. Decline — The De Novo request is declined. This can happen if the FDA determines that a predicate exists (directing you to 510(k)), that the device is high-risk and requires PMA, or that the evidence is insufficient to provide reasonable assurance of safety and effectiveness under general and special controls. A decline letter includes specific reasons and may suggest alternative pathways.

3. Withdrawal — The request is withdrawn, typically at the applicant's request. Withdrawal may be strategic — for example, if you learn during review that additional data is needed and you want to resubmit later rather than receive a decline.

The FDA provides written reasons for any decline, which can guide your next steps — whether that is additional data collection, a revised submission, or a different pathway. There is no formal appeals process specific to De Novo, but you can request a supervisory review of the decision or resubmit with additional information addressing the identified deficiencies.

What Happens After De Novo Authorization

A New Classification Regulation Is Created

Upon granting a De Novo request, the FDA issues a De Novo grant order that formally:

• Classifies the device type into Class I or Class II
• Assigns a new three-letter product code (e.g., QAS, QMT, QRZ)
• Establishes a new 21 CFR regulation number (or adds to an existing one)
• Defines the special controls applicable to the device type (for Class II)
• Identifies the review panel responsible for the device type

This is codified through a Federal Register notice and entry into the FDA's Product Classification Database. The classification applies not just to your specific device but to the entire device type as defined by the intended use and technological characteristics described in the classification regulation.

Your Device Becomes the First Predicate

The most significant consequence of a De Novo grant is that your device becomes the first legally marketed device in its product code. Future manufacturers who want to bring substantially equivalent devices to market can file 510(k) submissions using your De Novo device as the predicate.

This has strategic implications:

• You set the bar. The special controls you helped define will govern your competitors' submissions.
• Your data package sets expectations. If your De Novo included clinical data, subsequent 510(k) applicants may or may not need clinical data — the FDA will make that determination based on the classification regulation and special controls, not necessarily based on what you submitted.
• You define the product code. Your device's characteristics and intended use shape what will — and will not — be considered substantially equivalent in future 510(k) reviews.

Intellectual Property and Competitive Considerations

A De Novo grant does not confer any intellectual property rights. The product code, classification regulation, and special controls you helped establish are public and available to any manufacturer. Once your De Novo is granted, competitors can immediately begin developing 510(k) submissions using your device as a predicate.

This creates a strategic tension. The De Novo applicant bears the full cost and risk of establishing the new device category — the user fee, clinical studies, special controls development, and lengthy review timeline. Subsequent 510(k) applicants benefit from this work at a fraction of the cost (a $26,067 user fee and typically shorter review with less clinical data).

To protect your competitive position, consider:

• Patent protection — file patents on your device's unique technology, design, or methods before the De Novo grant makes your approach public
• First-mover advantage — use the time competitors need to develop their 510(k) submissions to establish market presence and clinical adoption
• Trade secrets — the De Novo Decision Summary is public, but your full submission is not. Proprietary manufacturing processes, algorithms, and know-how remain protected
• Special controls as barriers — well-designed special controls that reflect genuinely important safety requirements can create meaningful compliance hurdles for competitors, even if they are not explicitly designed as competitive barriers

Post-Market Obligations

After De Novo authorization, your post-market obligations are generally the same as for a 510(k)-cleared device:

• General controls compliance — registration and listing (21 CFR Part 807), labeling (21 CFR Part 801), Quality System Regulation / QMSR (21 CFR Part 820), Medical Device Reporting for adverse events (21 CFR Part 803), and corrections and removals reporting (21 CFR Part 806)
• Special controls compliance — ongoing adherence to all special controls defined in the De Novo grant order, including any post-market surveillance, labeling, or performance testing requirements
• No annual report requirement — unlike PMA-approved devices, De Novo-authorized devices do not require an annual report to the FDA
• Modification management — modifications may require a new 510(k) if they could significantly affect safety or effectiveness, or they can be documented via a letter-to-file if the modification is not significant. The assessment of significance should follow FDA's guidance on deciding when to submit a 510(k) for a change to an existing device

De Novo Statistics and Trends

Authorizations by Year

The De Novo pathway has seen dramatic growth, particularly after the FDASIA 2012 amendment introduced the direct De Novo option and after the 2017 final guidance formalized the process.

Year	De Novo Grants (Approx.)	Notable Trend
1998–2011	~3–5 per year	Post-NSE pathway only, low utilization
2012	~5	FDASIA creates direct De Novo option
2013–2016	~10–15 per year	Gradual adoption of direct pathway
2017	~20	Final guidance published
2018	~25	Apple Watch ECG, IDx-DR authorize via De Novo
2019	~25	Continued growth
2020	~30	Growth despite COVID-19 disruptions
2021	~25	Slight dip, longer review times due to pandemic
2022	~22	FDA finalizes 21 CFR Part 860 Subpart D
2023	~35	Record number, digital health devices dominate
2024	~47	Another record year, AI/ML devices prominent

Since the 2017 guidance, an average of approximately 26 De Novo requests per year have been classified, making the De Novo pathway roughly 0.9% the volume of the 510(k) pathway (which processes approximately 3,000–3,500 submissions annually). Despite its relatively small volume, De Novo punches far above its weight in regulatory significance because each grant creates a new device category.

De Novo Grants by Medical Specialty

Analysis of all De Novo requests from 1997 through 2023 reveals that submissions cluster heavily in specific medical specialty areas (as defined by the corresponding FDA advisory committee panels):

Medical Specialty	Share of De Novo Submissions
Microbiology	~14.4%
Neurology	~11.2%
General and Plastic Surgery	~10.7%
Gastroenterology / Urology	~8.5%
Clinical Chemistry	~7.8%
Cardiovascular	~6.9%
Radiology	~6%
All others (dental, molecular genetics, physical medicine, hematology, etc.)	Remaining ~34.5%

More than half of all De Novo submissions fall within five primary medical specialties. In contrast, areas such as dental, molecular genetics, physical medicine, and hematology each account for less than 2% of submissions. This concentration reflects which clinical areas are seeing the most novel device innovation and where existing product codes are least adequate to describe new technologies.

Since 2017, a notable shift has occurred: software-based medical devices (SaMD) and in vitro diagnostics (IVDs) have grown to represent a disproportionately large share of De Novo submissions, reflecting the broader digital health revolution and the novelty of many AI/ML and digital therapeutic applications.

Review Time Trends

Review times for De Novo have been a persistent challenge. While the MDUFA V performance goal targets 150 FDA days, actual calendar times have been significantly longer:

Metric	2022	2023	2024
Average total calendar days	~390	~387	~350 (estimated)
MDUFA V target	150 FDA days (70%)	150 FDA days (70%)	150 FDA days (70%)
Primary delay factor	AI response time	AI response time	AI response time

The gap between FDA days and calendar days is largely attributable to AI (Additional Information) request cycles. The review clock stops while the applicant prepares responses, which can take weeks or months. Well-prepared submissions with Pre-Sub alignment tend to have fewer AI rounds and shorter total calendar times.

A comprehensive analysis published in Nature Digital Medicine examining all De Novo requests from 1997 through 2023 found a median decision time of approximately 309 calendar days and a mean of approximately 338 calendar days. However, the range is enormous — from as few as 28 days (Apple Watch ECG App, DEN180044) to over 30 months for complex devices. The Apple Watch ECG and Irregular Rhythm Notification Feature De Novos remain outliers: their 28-day and 33-day review times respectively are the fastest De Novo decisions on record, reflecting Apple's substantial Pre-Sub engagement and the FDA's strategic prioritization of consumer cardiac monitoring devices.

Practical tip: The Viz HCM De Novo (2023) achieved an approximately 8-month total timeline, demonstrating that well-prepared submissions with clear Pre-Sub alignment can move through review significantly faster than average. The key factors were thorough Pre-Sub engagement, complete data at the time of submission, and rapid AI response turnaround.

Common Device Types

De Novo authorizations cluster in several technology areas:

• Digital health and SaMD — mobile medical applications, clinical decision support software, remote monitoring platforms
• AI/ML-enabled devices — autonomous diagnostic algorithms, computer-aided detection and diagnosis
• Novel diagnostics — new IVD assays, point-of-care tests, at-home testing platforms
• Wearable sensors — continuous monitoring devices, biosensors
• Novel therapeutic devices — neurostimulation, digital therapeutics, new modalities

Of AI/ML-enabled devices authorized through 2024, approximately 5% received De Novo authorization, while the remainder were cleared via 510(k) — largely because earlier De Novo grants created the product codes and predicates that subsequent AI/ML devices now reference.

Notable De Novo Authorizations

The following examples illustrate the breadth and significance of devices authorized through the De Novo pathway. Each one created a new device category that shaped the regulatory landscape for subsequent devices.

IDx-DR / LumineticsCore (DEN180001, 2018)

The first autonomous AI diagnostic system authorized by the FDA. IDx-DR (now LumineticsCore by Digital Diagnostics) detects diabetic retinopathy using retinal images captured with a Topcon TRC-NW400 camera. It was groundbreaking because the system provides a diagnosis without requiring clinician interpretation — a fully autonomous AI. The De Novo established product code PIB and classification regulation 21 CFR 886.1100.

Why it mattered: This De Novo established the regulatory framework for autonomous AI in medical diagnostics. The concept that an AI system could make a clinical determination without a physician in the loop was novel not just technologically but regulatorily. The special controls established through this De Novo — including requirements for clinical validation, algorithm transparency, and labeling that makes the autonomous nature clear to users — became the template for subsequent autonomous AI diagnostic devices.

Apple Watch ECG App (DEN180044, 2018)

Apple's ECG App received De Novo authorization as a software-only mobile medical application intended for use with the Apple Watch to create, record, and display a single-channel electrocardiogram similar to a Lead I ECG. A companion De Novo for the Irregular Rhythm Notification Feature (DEN180042) was granted concurrently. These De Novos created product codes QRZ and QMT, respectively.

Why it mattered: These authorizations opened the door for the entire consumer wearable cardiac monitoring category. Before Apple Watch ECG, no consumer-grade wearable had been authorized to provide ECG functionality directly to consumers. The product codes established by these De Novos have since been used as predicates by Samsung, Google/Fitbit, and other wearable manufacturers pursuing 510(k) clearances for similar features.

Dexcom Stelo Glucose Biosensor System (2024)

Dexcom's Stelo was authorized as an over-the-counter continuous glucose monitoring system designed for people with type 2 diabetes who do not use insulin, as well as individuals without diabetes seeking glucose monitoring.

Why it mattered: This De Novo expanded CGM technology from a prescription-only medical device for insulin-dependent patients into an over-the-counter consumer product for a much broader population. It established the regulatory framework for OTC glucose biosensor systems, including special controls addressing consumer use without physician supervision.

Viz HCM (2023)

Granted De Novo on August 3, 2023, Viz HCM is a cardiovascular machine learning-based notification software that detects the likelihood of hypertrophic cardiomyopathy (HCM) from routine echocardiograms. The De Novo established classification regulation 21 CFR 870.2380 and product code QXO. Notable for its rapid timeline — only approximately 8 months from submission to authorization.

Why it mattered: This demonstrated that a well-prepared De Novo with clear pre-submission alignment can move through review efficiently, even for an AI/ML device addressing a novel clinical indication. The 8-month timeline is among the fastest De Novo reviews on record for an AI/ML device.

Bose Hearing Aid (DEN180026, 2018)

The Bose Hearing Aid was the first FDA-authorized self-fitting, direct-to-consumer air-conduction hearing aid for adults with perceived mild-to-moderate hearing loss. Users could customize the device's settings through a mobile app without requiring a visit to a hearing healthcare professional.

Why it mattered: This De Novo established the regulatory framework for self-fitting hearing aids — a category that had not previously existed. By demonstrating that consumers could safely and effectively fit their own hearing aids using software-guided customization, it paved the way for the broader over-the-counter hearing aid market that Congress subsequently opened through legislation. The special controls established requirements for self-fitting validation, acoustic output limits, and consumer labeling.

Monarch eTNS System (DEN180041, 2019)

The Monarch external Trigeminal Nerve Stimulation (eTNS) System was authorized as the first non-drug, non-surgical treatment for pediatric ADHD (ages 7–12 years) in patients not currently taking prescription ADHD medication.

Why it mattered: This was a landmark De Novo for two reasons. First, it established a regulatory pathway for neurostimulation-based treatment of a common pediatric condition, expanding the therapeutic applications of neuromodulation beyond pain and movement disorders. Second, it represented one of the first De Novo authorizations specifically for a pediatric-only indication, demonstrating FDA's willingness to classify novel pediatric devices through the De Novo pathway. The clinical evidence included a prospective, randomized, double-blind, sham-controlled trial.

Natural Cycles Fertility App (DEN170052, 2018)

Natural Cycles was the first FDA-authorized mobile application intended for use as a method of contraception. The app uses a proprietary algorithm that analyzes daily basal body temperature measurements to identify fertile and non-fertile days.

Why it mattered: This De Novo was notable for its reliance on real-world evidence (RWE) as primary clinical evidence. Rather than a traditional prospective clinical trial, the sponsor analyzed retrospective usage data from approximately 15,000 users to support claims of safety and effectiveness. This demonstrated that real-world data, when sufficiently robust, can serve as the primary clinical evidence for a De Novo request — a precedent that has influenced subsequent SaMD submissions.

Genius Digital Diagnostics System with Cervical AI Algorithm (DEN210035, 2024)

The Genius Digital Diagnostics System was authorized as the first AI-assisted digital cytology platform to aid in cervical cancer screening. The system uses artificial intelligence to analyze digitized Pap smear slides and identify areas of interest for pathologist review.

Why it mattered: This De Novo established the regulatory framework for AI-assisted digital cytology — an area with enormous public health impact given the scale of cervical cancer screening programs. The special controls addressed AI algorithm validation, integration with digital pathology workflows, and requirements for pathologist oversight of AI-assisted results.

BrainSee Prognostic Software (DEN220066, 2024)

BrainSee was authorized as an AI tool that predicts the progression of mild cognitive impairment (MCI) toward Alzheimer's disease, using brain MRI data analyzed by machine learning algorithms.

Why it mattered: This represented one of the first De Novo authorizations for a prognostic (rather than diagnostic) AI tool in neurodegenerative disease. The distinction matters: prognostic devices predict future disease progression rather than detecting current disease, raising unique clinical validation and labeling challenges. The special controls required clinical performance testing demonstrating the algorithm's ability to predict cognitive decline within a defined timeframe.

Visby Medical At-Home STI Test (2025)

Received De Novo authorization in March 2025 as one of the first at-home sexually transmitted infection diagnostic tests, allowing consumers to test for STIs without visiting a healthcare provider.

Why it mattered: This represented a fundamental expansion of at-home diagnostic testing beyond common conditions like pregnancy and COVID-19 into sexually transmitted infections — a category with significant public health implications and unique regulatory considerations around direct-to-consumer molecular diagnostics.

AI/ML Devices Across Radiology

Radiology dominates the AI/ML device landscape, accounting for 76–84% of all AI/ML device authorizations. Many foundational product codes in AI-assisted radiology were established through De Novo grants — including computer-aided triage, detection, and diagnosis software — which then served as predicates for the hundreds of 510(k) clearances that followed. By mid-2025, over 870 AI/ML-enabled radiological devices had been authorized by the FDA.

This pattern illustrates the De Novo pathway's role as a "gateway" mechanism: a single De Novo creates the regulatory infrastructure that enables an entire product category to develop through the faster, less expensive 510(k) pathway. Of all AI/ML-enabled devices authorized through 2024, only about 5% used the De Novo pathway — the remaining 95% were 510(k) clearances that relied on predicates originally established through De Novo grants.

The De Novo "Family Tree" Effect

Several De Novo authorizations have generated extensive predicate lineages. For example, the product codes established by early AI-based radiology De Novos have been referenced by dozens of subsequent 510(k) submissions, creating "family trees" of devices that all trace back to a single De Novo grant. This cascading effect amplifies the significance of each De Novo — a single well-structured De Novo request can enable an entire market segment.

Common De Novo Pitfalls and Refusal Reasons

Refuse to Accept (RTA) Issues

The FDA may refuse to accept your De Novo request for the following reasons:

• Incomplete submission — missing required sections, incorrect format, or failure to use eSTAR (after October 1, 2025)
• Existing open submission — an open or pending 510(k), PMA, or reclassification petition for the same product or indication already exists
• Multiple device types — the De Novo request covers more than one distinct device type (each type requires its own De Novo)
• User fee not paid — submission will not be reviewed until the fee is received
• Unresolved prior deficiencies — the submitter has not responded to previously communicated deficiencies

Common Decline Reasons

• A predicate actually exists — the FDA identifies a legally marketed device that could serve as a predicate, meaning 510(k) is the appropriate pathway
• Insufficient evidence — the non-clinical or clinical data does not adequately support reasonable assurance of safety and effectiveness
• Risk too high for Class I or II — the device's risk profile requires PMA-level controls
• Poorly defined special controls — the proposed special controls are vague, incomplete, or do not adequately address identified risks
• Benefit-risk imbalance — the probable risks outweigh the probable benefits given the proposed controls
• Intended use issues — the intended use is too broad, too narrow, or poorly defined

Strategic Pitfalls

• Skipping the Pre-Sub — without FDA alignment on pathway, testing, and special controls, you are building a submission blind. The risk of a major deficiency or decline increases substantially. This is the single most common and most costly mistake in the De Novo process.

• Underestimating timeline — the 150-day FDA review clock does not reflect total calendar time. Plan for 12–18 months from initial submission to grant, including AI response time. Factor in 60–90 days for Pre-Sub and 3–6 months for submission preparation. Total project timeline from concept to market can be 24–36 months.

• Insufficient predicate search — a cursory search that misses a relevant predicate will derail your submission. The FDA has access to databases and institutional knowledge you may not. A thorough predicate search requires searching multiple databases, using varied search terms, and considering devices with similar (not just identical) intended uses.

• Copying 510(k) conventions — De Novo requires fundamentally different thinking. You are not demonstrating equivalence — you are building the case for a new classification from scratch. The burden of proof and the content requirements are different. The benefit-risk determination, special controls proposal, and classification recommendation sections have no equivalent in a 510(k).

• Not budgeting for clinical data — approximately 80% of De Novo submissions include clinical studies. If you assume you can avoid clinical data without confirming this with FDA through a Pre-Sub, you may face significant delays and cost overruns.

• Overly broad or vague intended use — because the intended use statement becomes the legal basis for the classification regulation, FDA will scrutinize it carefully. An overly broad intended use may prompt FDA to require more extensive evidence. An overly narrow intended use may unnecessarily limit your commercial opportunities.

• Weak benefit-risk analysis — the benefit-risk determination in a De Novo is not a formality. FDA evaluates whether the probable benefits to health from the use of the device outweigh the probable risks when the device is used with the proposed special controls. A poorly constructed benefit-risk analysis is a frequent source of AI requests and a potential basis for decline.

• Ignoring labeling — labeling is a special control. For De Novo devices, the labeling must clearly communicate the intended use, patient population, clinical setting, limitations, and warnings. FDA reviews De Novo labeling with particular care because it is establishing the labeling standards for an entire device category.

• Not reviewing prior De Novo decisions — the FDA's publicly available De Novo Decision Summaries are an invaluable resource. Before preparing your submission, review De Novo grants for devices in similar clinical areas or with similar technology. These summaries reveal the types of evidence FDA accepted, the special controls that were established, the clinical study designs that were sufficient, and the labeling requirements that were imposed. This regulatory intelligence can directly inform your submission strategy, testing plan, and special controls proposal. Access the FDA's De Novo database at accessdata.fda.gov and search by medical specialty, product code, or device name.

Pre-Submission (Q-Sub) for De Novo: Why It Is Critical

The Pre-Submission (Q-Sub) program allows you to submit questions to the FDA and receive written feedback before you file your De Novo request. For De Novo, a Pre-Sub is more important than for any other submission type, for several reasons:

1. Pathway confirmation — The FDA confirms that De Novo is appropriate and that no predicate exists. This prevents the most expensive mistake: building a De Novo submission when a 510(k) would suffice (or when a PMA is actually required).

2. Classification alignment — You and FDA agree on whether the device should be Class I or Class II, which determines whether you need to develop special controls.

3. Testing strategy — FDA provides feedback on your proposed non-clinical testing plan and whether clinical data is needed. For De Novo devices, there are often no established guidance documents or recognized standards that directly apply. The Pre-Sub fills this gap.

4. Special controls feedback — You can propose draft special controls and get FDA feedback before you finalize them, ensuring your proposal aligns with FDA expectations.

5. Intended use precision — The intended use statement in a De Novo becomes the foundation of a new classification regulation. Getting FDA agreement on the language before submission is essential.

The typical Pre-Sub timeline is 60–90 days from submission to feedback meeting. You can submit multiple Pre-Subs — an initial one early in development and a follow-up closer to submission. For complex De Novo devices, two or more Pre-Sub interactions are common and advisable.

What to Include in Your De Novo Pre-Sub

Your Pre-Sub package should include enough information for the FDA to provide meaningful feedback. For a De Novo Pre-Sub, this typically means:

• Device description and intended use — sufficient detail for FDA to understand what the device does and who it is for
• Proposed classification — your recommendation for Class I or Class II, with rationale
• Predicate search results — a summary of your search demonstrating that no predicate exists
• Proposed special controls — a draft list of special controls you plan to propose (for Class II)
• Proposed testing plan — a summary of your planned non-clinical and clinical testing, including study design if a clinical study is proposed
• Specific questions — clearly numbered questions for the FDA to address. Be specific: "Do you agree that De Novo is the appropriate pathway?" is better than "What pathway should we use?" The more precise your questions, the more actionable the FDA's feedback will be.

How to Structure Pre-Sub Questions

Experienced regulatory professionals structure Pre-Sub questions to elicit specific, actionable feedback. Effective De Novo Pre-Sub questions include:

• "We have conducted a predicate search using [databases and terms]. We did not identify a suitable predicate. Do you agree that De Novo is the appropriate pathway for this device?"
• "We propose classifying this device as Class II with the special controls listed in Section X of this submission. Do you agree with this classification? If not, what classification do you recommend?"
• "We propose the following non-clinical testing plan [summary]. Is this testing sufficient, or does the FDA recommend additional testing?"
• "Based on the intended use and risk profile described, does the FDA believe clinical data is necessary to support this De Novo request? If so, do you have feedback on the proposed study design outlined in Section Y?"
• "We propose the following intended use statement: [exact text]. Does the FDA agree with this language? If modifications are recommended, please provide suggested alternative language."

Practical tip: Do not ask open-ended questions like "What should we do?" or "What data do you need?" The FDA responds best to specific proposals that they can agree with, modify, or disagree with. Present your regulatory strategy and ask the FDA to validate or redirect it.

Key FDA Guidance Documents for De Novo

The following guidance documents are essential reading for anyone preparing a De Novo submission:

Guidance Document	Year	Relevance
De Novo Classification Process (Evaluation of Automatic Class III Designation)	2021 (final)	The primary guidance for De Novo submission and review procedures
Acceptance Review for De Novo Classification Requests	2019 (final)	Describes the acceptance review criteria and common RTA reasons
Electronic Submission Template for Medical Device De Novo Requests	2024 (final)	eSTAR template requirements, mandatory as of October 1, 2025
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program	2023 (revised final)	Governs the Pre-Sub process critical for De Novo preparation
The 510(k) Program: Evaluating Substantial Equivalence	2014 (final)	Understanding SE helps articulate why De Novo is needed
Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement	2023 (final)	Framework for the benefit-risk analysis required in De Novo
Marketing Submission Recommendations for a Predetermined Change Control Plan for AI/ML-Enabled Device Software Functions	2024 (final)	PCCP guidance relevant for AI/ML devices pursuing De Novo
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions	2023 (final)	Cybersecurity documentation requirements for connected devices
Content of Premarket Submissions for Device Software Functions	2023 (final)	Software documentation requirements applicable to SaMD De Novo submissions
User Fees and Refunds for De Novo Classification Requests	2022 (revised)	Identifies fee requirements, exceptions (including pediatric), and refund eligibility
Patient Preference Information — Voluntary Submission, Review in PMAs, HDEs, and De Novo Requests	2016 (final)	Guidance on including patient preference data to support benefit-risk determinations
FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals	2022 (revised)	Details how sponsor and FDA actions affect the review clock, including the 180-day response deadline
Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices	2017 (final)	Interoperability documentation for connected De Novo devices
Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications [510(k)] with Different Technological Characteristics	2023 (final)	Helps articulate benefit-risk framework relevant to De Novo classification arguments

These documents, along with device-specific guidance for your product area, form the regulatory foundation for a De Novo submission. Check the FDA's guidance database for updates — guidance documents are revised periodically.

Breakthrough Device Designation and De Novo

The FDA's Breakthrough Devices Program is a separate designation that can be paired with any premarket submission pathway, including De Novo. Breakthrough status is not a pathway — it is a program that overlays additional FDA engagement and expedited review onto your existing pathway.

Eligibility

To qualify for Breakthrough Device Designation, your device must:

• Provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition, and
• Meet at least one of the following: represent a breakthrough technology, have no approved or cleared alternatives, offer significant advantages over existing alternatives, or be in the best interest of patients

Benefits When Combined with De Novo

• Increased FDA interaction — more frequent and collaborative communication with the review team
• Expedited review — prioritized review timeline
• Flexible clinical study design — FDA may accept novel clinical evidence approaches
• Senior management involvement — escalation paths within FDA leadership
• Priority review of manufacturing — expedited facility inspections

Timing

Submit your Breakthrough Device Designation request before filing the De Novo. This allows you to take advantage of all Breakthrough benefits during the Pre-Sub process and throughout the substantive review. The FDA recommends that the designation request be submitted during the early development phase.

Many notable De Novo authorizations in the AI/ML and digital health space have combined Breakthrough designation with the De Novo pathway, leveraging the expedited interactions to navigate the inherent complexity of establishing a new device category.

Practical Considerations for Breakthrough + De Novo

Combining Breakthrough designation with a De Novo submission requires careful coordination:

• Separate submissions: The Breakthrough designation request and the De Novo request are separate submissions. The Breakthrough request should be submitted first, ideally during early development, so that you can benefit from the expedited Pre-Sub interactions.

• Sprint discussions: Breakthrough-designated devices are eligible for "sprint discussions" — focused FDA meetings to resolve specific scientific or regulatory questions. These are particularly valuable for De Novo devices where the regulatory framework is being established for the first time.

• Data development protocol: For Breakthrough devices, the FDA may agree to a "data development protocol" that outlines the evidence needed for authorization. For De Novo, this effectively means the FDA pre-commits to the evidence package before you generate it — reducing the risk of unexpected data requests during review.

• Not all De Novo devices qualify: Breakthrough designation requires that the device address a life-threatening or irreversibly debilitating condition. Many De Novo devices address lower-risk conditions and may not meet this threshold. Do not pursue Breakthrough designation unless your device genuinely qualifies — submitting an ineligible request wastes time and can create a negative impression with the review team.

International Implications of De Novo Authorization

FDA De Novo Does Not Equal Global Authorization

A De Novo grant authorizes marketing only in the United States. There is no mutual recognition agreement between the FDA and the EU, Japan, or most other major markets that would allow a De Novo grant to serve as the basis for automatic market access elsewhere.

However, De Novo authorization does carry practical strategic value internationally:

• Clinical data reuse — Clinical studies conducted to support a De Novo request can often support submissions in other markets (EU MDR clinical evaluations, PMDA applications in Japan, Health Canada license applications), though additional data or different analysis formats may be required.

• Technical documentation leverage — The substantial technical file developed for a De Novo — including risk analysis, performance testing, and design documentation — aligns well with the requirements for EU MDR technical documentation, ISO 13485 design history files, and regulatory submissions in other markets.

• Regulatory credibility — FDA authorization (of any type) is widely recognized as a signal of rigorous regulatory review. Several markets, including Singapore (HSA), Australia (TGA), and some Middle Eastern regulators, offer expedited review pathways for devices that already hold FDA clearance or authorization.

• Product code and classification — The product code and classification regulation established through a De Novo provide a clear, FDA-endorsed description of the device type and its risk profile, which can help structure regulatory strategy in other markets.

EU MDR Considerations

For companies pursuing both FDA De Novo and EU MDR CE marking, note that the European pathway does not have a direct equivalent of De Novo. Under EU MDR, novel devices are classified according to the classification rules in Annex VIII regardless of whether a similar device has been marketed before. The concept of "predicate" does not exist in EU MDR — instead, you must demonstrate conformity with General Safety and Performance Requirements (GSPRs) through a conformity assessment involving a Notified Body (for Class IIa and above).

The clinical evaluation requirements under EU MDR (Article 61) are typically more extensive than what the FDA requires for a De Novo, particularly regarding post-market clinical follow-up (PMCF) commitments.

Other Major Markets

Market	Equivalent Pathway	FDA De Novo Leverage
EU (MDR)	No equivalent; classification per Annex VIII rules	Clinical data and technical documentation can be adapted; no expedited pathway for FDA-authorized devices
Japan (PMDA)	Shonin approval for new devices	Clinical data can be referenced; PMDA conducts independent review. Harmonized standards (IEC, ISO) reduce redundant testing
Canada (Health Canada)	Class III/IV medical device license	MDSAP audit covers FDA and Health Canada quality requirements simultaneously
Australia (TGA)	Inclusion in ARTG	TGA offers expedited review for devices with FDA clearance/authorization under some circumstances
Singapore (HSA)	Product registration	HSA fast-tracks registration for devices with FDA authorization
South Korea (MFDS)	New device approval	Independent review required; clinical data may be referenced
China (NMPA)	Registration for new Class II/III devices	In-country clinical trials may be required regardless of FDA authorization

Global Regulatory Strategy Recommendations

For companies with De Novo devices, consider the following global strategy elements:

1. Sequence your submissions strategically. Many companies pursue FDA first because the De Novo process generates comprehensive technical and clinical documentation that can be leveraged for other markets. However, if the EU is your primary revenue market, starting with MDR may make more sense given the longer Notified Body timelines.

2. Design clinical studies to serve multiple regulatory purposes. If you need a clinical study for your De Novo, design it to also satisfy EU MDR clinical evaluation requirements and other market-specific requirements. This may mean enrolling sites in multiple geographies, using endpoints acceptable to multiple regulators, and following GCP requirements that satisfy both FDA and international standards.

3. Invest in MDSAP if you serve multiple markets. The Medical Device Single Audit Program (MDSAP) allows a single quality system audit to satisfy requirements for the US (FDA), Canada (Health Canada), Brazil (ANVISA), Japan (PMDA), and Australia (TGA). For a De Novo device manufacturer expanding internationally, MDSAP reduces the audit burden significantly.

De Novo and Software as a Medical Device (SaMD)

Software as a Medical Device (SaMD) — software intended to be used for medical purposes without being part of a hardware medical device — is one of the most active categories for De Novo submissions. The intersection of novel software functionality and the lack of existing product codes makes De Novo the natural pathway for many SaMD products.

Why SaMD Frequently Requires De Novo

Most SaMD products perform functions that did not exist when the FDA's product classification database was established. An AI algorithm that detects a disease from medical images, a digital therapeutic that treats a behavioral health condition through a smartphone app, or a clinical decision support tool that integrates multiple data sources to recommend treatment — none of these fit neatly into existing product codes because the product codes were created for hardware devices.

When no existing product code describes your SaMD's intended use and technological characteristics, De Novo is the pathway to create one.

SaMD-Specific De Novo Considerations

• Software level of concern / risk categorization: The FDA categorizes SaMD risk based on the significance of the information provided by the SaMD to the healthcare decision and the state of the healthcare situation or condition. Higher-risk SaMD (e.g., autonomous diagnosis of a serious condition) will require more robust clinical evidence than lower-risk SaMD (e.g., clinical decision support for a non-serious condition).

• Algorithm description and transparency: For AI/ML-based SaMD, the FDA expects a detailed description of the algorithm, including training data characteristics, validation methodology, performance metrics, and known limitations. This is particularly important for De Novo because you are establishing the transparency expectations for the entire product code.

• Cybersecurity: Connected SaMD must address cybersecurity requirements per FDA's premarket cybersecurity guidance. Cybersecurity controls are frequently included as special controls in SaMD De Novo grants.

• Predetermined Change Control Plans (PCCPs): SaMD manufacturers should consider including a PCCP in their De Novo submission. This pre-authorizes certain types of algorithm updates (within defined boundaries) without requiring a new marketing submission, which is essential for AI/ML devices that improve over time.

• Real-World Performance Monitoring: The FDA may include post-market performance monitoring as a special control for SaMD De Novo devices, particularly for AI/ML products where performance may vary across different populations or clinical settings.

Notable SaMD De Novo Product Codes

Several De Novo grants have created product codes that now serve as the regulatory home for large categories of SaMD:

• QAS — Radiological computer-assisted diagnostic (CADx) software
• QMT — Irregular rhythm notification software (wearable)
• QRZ — Electrocardiograph software for over-the-counter use
• PIB — Autonomous AI-based diagnostic software
• QXO — Cardiovascular machine learning-based notification software

Each of these product codes was created through a single De Novo grant and has since been referenced by multiple subsequent 510(k) submissions.

De Novo for Combination Products

The 2021 final rule (21 CFR Part 860, Subpart D) explicitly provides that certain combination products can obtain marketing authorization through the De Novo classification process. This is relevant for device-led combination products — products where the device constituent part is the primary mode of action and a drug or biologic constituent part is secondary.

When De Novo Applies to Combination Products

De Novo is appropriate for a combination product when:

• The primary mode of action is that of a device (making it a device-led combination product)
• The device constituent part is novel with no existing predicate
• The combination product is low-to-moderate risk overall
• General controls or general and special controls can provide reasonable assurance of safety and effectiveness

Examples include drug-eluting devices where the device platform is novel, or diagnostic devices that incorporate reagents or biological components as integral parts of a novel testing platform.

Additional Considerations for Combination Product De Novo

• Lead center coordination — For device-led combination products, CDRH is typically the lead center. However, consultation with CBER or CDER may be required for the drug or biologic constituent. The Pre-Sub is essential for establishing the lead center and consultation framework.
• Constituent part requirements — The De Novo must address safety and effectiveness of the combination product as a whole, including the drug or biologic constituent part. This may require additional data beyond what a standalone device De Novo would need.
• Special controls for both constituents — Special controls may need to address both the device and drug/biologic aspects, including manufacturing controls for the drug constituent, biocompatibility of the combined product, and compatibility testing between constituents.

De Novo for Startups and Small Companies

The De Novo pathway presents unique challenges and opportunities for startups and small medical device companies. Many of the most innovative De Novo devices come from smaller companies — startups are disproportionately likely to bring truly novel devices to market because they are developing new technologies rather than iterating on existing ones.

Small Business Fee Reduction

Small businesses qualifying through the FDA's Small Business Determination (SBD) program pay a significantly reduced De Novo user fee — $43,446 vs. the standard $173,782 in FY2026 (a 75% discount). To qualify, your company must have gross receipts or sales of $100 million or less. Apply for SBD determination well before your planned submission date, as processing takes time.

Additionally, beginning in FY2026, the FDA is offering a waiver of the Annual Establishment Registration Fee ($11,423) for qualifying small businesses with gross receipts and sales of $1 million or less that can demonstrate financial hardship.

Practical Advice for Resource-Constrained Teams

1. Prioritize the Pre-Sub above all else. For a startup with limited resources, the Pre-Sub is the highest-ROI activity in the entire De Novo process. It confirms your pathway, clarifies testing requirements, and prevents costly misdirection.

2. Engage experienced regulatory consultants. De Novo is not the submission type to learn on. The complexity of special controls development, benefit-risk analysis, and classification recommendation requires experience with the pathway. Budget for senior regulatory expertise — it will save money in the long run by reducing AI rounds and preventing declines.

3. Consider Breakthrough Device Designation. If your device qualifies, Breakthrough designation provides expedited FDA interactions at no additional cost. This is particularly valuable for startups that benefit from more frequent and collaborative FDA communication.

4. Plan your IP strategy before submission. Remember that the De Novo Decision Summary is public. File your patents before the De Novo is granted to protect your competitive position. Once your device is authorized, competitors can begin developing 510(k) submissions using your device as a predicate.

5. Factor in the full timeline. From first Pre-Sub to De Novo grant typically takes 18–30 months. Ensure your funding runway accounts for this timeline, including clinical study costs, AI response preparation, and potential delays.

6. Use the FDA's resources. The FDA offers free CDRH Learn webinars, guidance documents, and a dedicated Division of Industry and Consumer Education (DICE) that can answer general questions about the De Novo process. These resources are particularly valuable for first-time submitters.

Comprehensive Comparison: De Novo vs. 510(k) vs. PMA

Factor	De Novo	510(k)	PMA
Legal basis	Section 513(f)(2) FD&C Act	Section 510(k) FD&C Act	Section 515 FD&C Act
Device risk class	Novel Class I or II	Class I (non-exempt), Class II	Class III
Predicate required?	No (you become the predicate)	Yes	No
Standard of review	Reasonable assurance of safety & effectiveness	Substantial equivalence to predicate	Reasonable assurance of safety & effectiveness
FDA action term	"Granted"	"Cleared"	"Approved"
Clinical data typically required?	Often (~80% include clinical data)	Sometimes (device-dependent)	Almost always
Non-clinical testing	Extensive (establishing new requirements)	Moderate (matching predicate expectations)	Extensive
Special controls	You propose them (for Class II)	Existing special controls apply	N/A (Class III has PMA requirements)
User fee FY2026 (standard)	$173,782	$26,067	$579,272
User fee FY2026 (small business)	$43,446	$6,517	$144,818
FDA review goal	150 FDA days (MDUFA V)	90 FDA days	180 FDA days
Typical total calendar time	12–18 months	4–8 months	12–24+ months
Pre-Sub recommended?	Strongly recommended (essentially mandatory)	Recommended for complex devices	Strongly recommended
eSTAR required?	Yes (as of Oct 1, 2025)	Yes (as of Oct 1, 2023)	No (eCopy)
Creates new product code?	Yes	No	No (but may modify classification)
Creates predicate for future devices?	Yes	No (but your device can serve as predicate)	No
Annual reporting	No	No	Yes (PMA annual report)
Post-authorization changes	New 510(k) or letter-to-file	New 510(k) or letter-to-file	PMA supplement
Third-party review eligible?	No	Yes (for some device types)	No
Advisory panel meeting	Rare	Rare	Sometimes (for novel Class III)
Breakthrough designation eligible?	Yes	Yes	Yes
Inspection before decision	Sometimes (novel processes)	Rare	Often
PCCP eligible?	Yes (for software/AI devices)	Yes (for software/AI devices)	Yes (for software/AI devices)
Typical total project cost	$300K–$3M+	$50K–$500K	$500K–$10M+
Best for	Novel low/moderate-risk devices with no predicate	Devices with existing predicates	High-risk or life-sustaining devices

Checklist: Are You Ready to Submit a De Novo?

Before filing your De Novo request, confirm that you have completed or addressed each of the following:

• Predicate search completed and documented — you have searched the FDA databases thoroughly and confirmed that no suitable predicate exists
• Pre-Submission feedback received — you have obtained FDA alignment on pathway, intended use, testing plan, and special controls through at least one Pre-Sub
• Intended use statement finalized — reviewed by regulatory counsel, aligned with Pre-Sub feedback, and precise enough to serve as the basis of a classification regulation
• Special controls drafted — mapped to identified risks, specific and measurable, referencing recognized standards where applicable
• Non-clinical testing complete — all bench performance, biocompatibility, electrical safety, EMC, software V&V, cybersecurity, and other applicable testing is done and reports are finalized
• Clinical data generated (if applicable) — clinical study completed, data analyzed, report written, and adverse events documented
• Benefit-risk determination written — clear articulation of probable benefits and risks, with analysis demonstrating that benefits outweigh risks under the proposed controls
• Labeling finalized — including instructions for use, warnings, contraindications, and patient-facing materials
• eSTAR template completed — all sections filled out, technical screening passed, files properly formatted
• User fee payment arranged — fee identified (standard or small business rate) and payment mechanism in place
• Quality system compliant — manufacturing facility is operating under a compliant QMS and is inspection-ready
• IP strategy executed — patents filed before the De Novo Decision Summary becomes public

Frequently Asked Questions

1. What does "De Novo" actually mean?

"De Novo" is Latin for "anew" or "from the beginning." In the FDA context, it refers to classifying a device from scratch — creating a new classification category rather than fitting the device into an existing one through comparison to a predicate.

2. Can I submit a De Novo directly, or do I need to get an NSE determination first?

Since the 2012 FDASIA amendment, you can submit a De Novo request directly without first filing a 510(k) and receiving a Not Substantially Equivalent (NSE) determination. The original post-NSE route still exists under Section 513(f)(2)(A), but the direct route under Section 513(f)(2)(B) is now used for the vast majority of De Novo requests.

3. How long does the De Novo process take from start to finish?

Plan for 12–18 months from submission to grant as a realistic timeline for a well-prepared De Novo request. The MDUFA V performance goal is 150 FDA days for substantive review, but the total calendar time is typically longer due to Additional Information (AI) request rounds during which the review clock stops. Historical average total calendar time has been approximately 350–420 days. Adding Pre-Sub time (60–90 days) and preparation time, the overall timeline from project start to market authorization is often 18–30 months.

4. Is clinical data always required for a De Novo?

No, but it is needed in the majority of cases. Approximately 80% of De Novo submissions include clinical data. Whether clinical data is required depends on the device's risk profile, intended use, and whether non-clinical evidence alone provides reasonable assurance of safety and effectiveness. The best way to determine clinical evidence requirements is through a Pre-Submission meeting with the FDA.

5. What happens if my De Novo is declined?

If your De Novo request is declined, the FDA provides written reasons for the decision. Depending on the reason, you may be able to collect additional data and resubmit, modify your intended use or proposed classification and resubmit, switch to the 510(k) pathway (if a predicate was identified), or switch to the PMA pathway (if the device is deemed high-risk). A decline does not prevent future submissions — it provides information to guide your revised strategy.

6. Can a De Novo device serve as a predicate for a competitor's 510(k)?

Yes. This is one of the most significant consequences of a De Novo grant. Once your device is authorized and a new product code is established, any manufacturer can use your device as a predicate for a 510(k) submission for a substantially equivalent device. You do not have exclusive rights to the product code or classification — the De Novo creates a public regulatory framework.

7. Do De Novo devices need to comply with the Quality System Regulation (QSR)?

Yes. De Novo-authorized devices are subject to the same general controls as all FDA-regulated devices, including the Quality System Regulation (21 CFR Part 820), which is transitioning to the Quality Management System Regulation (QMSR) harmonized with ISO 13485. Additionally, Class II De Novo devices must comply with the specific special controls established in the De Novo grant order.

8. Can I get Breakthrough Device Designation for a De Novo device?

Yes. Breakthrough Device Designation can be combined with any premarket pathway, including De Novo. If your device meets the Breakthrough criteria (more effective treatment or diagnosis of a life-threatening or irreversibly debilitating condition, plus at least one additional criterion), you should consider requesting designation before filing the De Novo. Breakthrough provides expedited interactions, priority review, and more collaborative FDA engagement.

9. What is the difference between a De Novo and a reclassification petition?

A De Novo request classifies a new device type that has no existing classification. A reclassification petition asks the FDA to change the classification of a device type that is already classified — for example, moving a device from Class III to Class II. Reclassification is governed by Section 513(e) of the FD&C Act and follows a different process involving public notice and comment. De Novo and reclassification can have similar outcomes (a device ending up in Class II with special controls), but they start from different places.

10. How does the Predetermined Change Control Plan (PCCP) apply to De Novo devices?

The FDA finalized guidance on Predetermined Change Control Plans (PCCPs) in December 2024. PCCPs allow manufacturers to pre-specify how AI/ML algorithms or other device software functions will be updated post-market without requiring a new marketing submission for each change. PCCPs can be included in De Novo submissions, allowing the De Novo grant to prospectively authorize certain types of modifications. This is particularly relevant for AI/ML-enabled devices going through De Novo. A well-crafted PCCP can significantly reduce the post-market regulatory burden for software devices by pre-defining the boundaries within which algorithm updates can be made without a new submission.

11. How many De Novo requests does the FDA receive and grant each year?

The number of De Novo grants has grown significantly over the past decade. In 2024, the FDA granted approximately 47 De Novo requests — a record high. For comparison, fewer than 5 per year were filed through most of the 2000s. The growth has been driven by digital health, AI/ML devices, and novel diagnostics. The De Novo pathway still represents less than 1% of the total volume of FDA device marketing authorizations, but its regulatory impact is outsized because each grant creates a new device category.

12. Can I submit a De Novo for an IVD (in vitro diagnostic) device?

Yes. IVD devices that are novel and low-to-moderate risk can be authorized through the De Novo pathway, just like other medical devices. Several notable IVDs have been authorized via De Novo, including novel diagnostic tests for conditions where no previous test existed or where the testing context was fundamentally new (such as at-home molecular diagnostics). IVD De Novo submissions are reviewed by the Office of In Vitro Diagnostics (OHT7) within CDRH, and the content requirements follow the same framework as other De Novo requests, with additional IVD-specific considerations such as analytical performance validation (sensitivity, specificity, accuracy, precision, linearity, interfering substances).

13. What is the difference between a "direct" De Novo and a "post-NSE" De Novo?

The "post-NSE" (post-Not Substantially Equivalent) route is the original pathway established by FDAMA in 1997. Under this route, you first submit a 510(k), receive an NSE determination, and then submit a De Novo request within 30 days. The "direct" route, added by FDASIA in 2012, allows you to submit a De Novo request directly without first going through a 510(k). The direct route is now used for the vast majority of De Novo submissions. The post-NSE route is rarely used and is generally only relevant when a manufacturer genuinely believed a 510(k) was appropriate but received an unexpected NSE determination.

14. Can a foreign company submit a De Novo request to the FDA?

Yes. Any person, including foreign manufacturers, can submit a De Novo request to the FDA. Foreign companies must designate a US Agent for FDA communications and comply with US establishment registration and device listing requirements. Foreign clinical data can be used to support the submission, subject to FDA's requirements for acceptance of foreign clinical data. The device must meet all applicable US requirements, including labeling in English.

De Novo in the Context of FDA Modernization

The De Novo pathway has evolved from an obscure regulatory footnote into a central pillar of FDA's device authorization framework. Several ongoing and anticipated developments will continue to shape how De Novo is used in the coming years.

MDUFA V Performance Goals and Accountability

MDUFA V (FY2023–FY2027) introduced the first formal performance goals specific to De Novo. The 150-FDA-day target with 70% compliance, escalating to potentially 80–90% in later fiscal years, represents a commitment by both FDA and industry to make the De Novo process more predictable and timely. Under MDUFA V, outcome goals are shared between FDA and industry — meaning that industry's responsiveness to AI requests also factors into performance measurement. If a company takes six months to respond to an AI request, that delays the calendar time but not the FDA day count.

The Growing Role of Real-World Evidence

The FDA has been increasingly receptive to real-world evidence (RWE) in device submissions, including De Novo requests. The 2024 finalization of RWE guidance for device sponsors opens the door for De Novo applicants to supplement or, in some cases, substitute traditional clinical trial data with real-world data from registries, electronic health records, and post-market surveillance databases. This is particularly relevant for De Novo devices where conducting a traditional randomized controlled trial may be impractical due to the novelty of the device or the absence of a standard-of-care comparator.

Total Product Lifecycle (TPLC) Approach

FDA's Total Product Lifecycle approach — which considers a device from initial design through post-market surveillance and eventual obsolescence — is particularly relevant for De Novo. Because the De Novo applicant establishes the regulatory framework for a new device category, the special controls defined at authorization must anticipate the lifecycle needs of the technology. This means special controls increasingly include provisions for:

• Post-market performance monitoring
• Software update pathways (PCCPs)
• Adverse event surveillance specific to the novel technology
• Periodic reassessment of benefit-risk as clinical experience accumulates

Impact of FDA Workforce and Budget Changes

The FDA's device review capacity can fluctuate based on Congressional appropriations, user fee revenue, and workforce changes. Any reductions in review staff can disproportionately affect De Novo review times because De Novo requests are more complex and resource-intensive than 510(k) reviews. Applicants should monitor FDA's operational status and plan submission timing accordingly, particularly during periods of budget uncertainty.

Key Takeaways

1. De Novo is a classification pathway, not just a marketing authorization. A successful De Novo creates a new product code, a new classification regulation, and defined special controls that govern an entire device category.

2. Use De Novo when your device is novel and low-to-moderate risk with no legally marketed predicate. Do not force a 510(k) when no true predicate exists — the FDA will reject it.

3. The Pre-Submission meeting is essentially mandatory. For De Novo, the Pre-Sub is where you validate your pathway choice, testing plan, special controls, and clinical evidence strategy. Skipping it is the single biggest source of preventable delays.

4. Plan for 12–18 months and budget accordingly. The user fee alone is $173,782 (FY2026 standard rate). Add clinical studies, testing, and regulatory preparation costs on top. De Novo is significantly less expensive than PMA but substantially more than 510(k).

5. Approximately 80% of De Novo requests include clinical data. Assume you will need clinical evidence unless FDA confirms otherwise in a Pre-Sub.

6. Your special controls become the law of the land for your device category. Take them seriously — they will govern your competitors' submissions and your own future modifications.

7. De Novo volume is growing rapidly — from fewer than 5 per year before 2012 to approximately 47 in 2024. Digital health, AI/ML, and novel diagnostics are the primary drivers.

8. Consider Breakthrough Device Designation if your device qualifies. Pairing Breakthrough with De Novo provides expedited FDA interactions and priority review for establishing new device categories.

9. De Novo authorization is US-only. Plan your global regulatory strategy separately — clinical data and technical documentation can be leveraged, but additional submissions are required for EU (MDR), Japan (PMDA), and other markets.

10. eSTAR is now mandatory. As of October 1, 2025, all De Novo submissions must use the electronic submission template and be filed through the CDRH Customer Collaboration Portal.

11. The De Novo pathway is growing in importance. As novel technologies like AI/ML, digital therapeutics, wearable biosensors, and at-home diagnostics continue to emerge, De Novo will remain the gateway for establishing new device categories. Understanding this pathway is increasingly essential for regulatory professionals working in innovation-driven segments of the medical device industry.

12. Plan your global regulatory strategy alongside your De Novo. The clinical and technical data you generate for your De Novo can be leveraged for submissions in the EU (MDR), Japan (PMDA), Canada, Australia, and other markets — but only if you plan for this from the beginning. Designing clinical studies that serve multiple regulatory purposes and building technical documentation that meets international standards will save significant time and cost across your global launch.